Lan Huang
Co-Founder, Chairman & Chief Executive Officer Seed Therapeutics
Seminars
Wednesday 28th October 2026
Reimagining What is Druggable: From Molecular Glue Discovery to Clinical Medicines
11:45 am
- Molecular glues, as a new class of modalities, are transforming the boundaries of drug discovery, with the potential to target 80% undruggable targets
- SEED has built a scalable RITE3 engine to covert induced-proximity science with novel E3s into medicine candidates for a broad range of high value targets in oncology and neurodegeneration and beyond
- SEED is translating this vision into clinical reality, with its first molecular glue degrader for oncology in the clinic demonstrating precise target engagement
